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Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate incretin hormones and exert anti-diabetic effects
in type 2 diabetes mellitus. Treatment with angiotensin II type 1 receptor blockers (ARB) is a proven successful
intervention for hypertension with type 2 diabetes. The present study investigated the combined effects of the
DPP-4 inhibitor vildagliptin and the ARB valsartan in a mouse model of type 2 diabetes.
Methods: C57BL/6 J mice fed with high-fat diet (HFD) or db/db mice were treated with placebo, phloridzin (PHZ),
vildagliptin alone (ViL), valsartan alone (VaL) or ViL with VaL (ViLVaL) for 8 weeks.
Results: Glucose metabolism was improved in response to PHZ, ViL and ViLVaL in both HFD and db/db mice.
Upon glucose challenge, ViLVaL showed the greatest suppression of blood glucose excursions, with increased
insulin secretion, in db/db mice. ViLVaL treatment also showed an improvement of insulin sensitivity in db/db mice.
Serum inflammatory cytokines were significantly decreased, and adiponectin was highest, in the ViLVaL group.
ViLVaL improved insulin signaling and attenuated stress signaling in liver with amelioration of hepatic steatosis due
to activated fatty acid oxidation in db/db mice. Furthermore, immunohistochemical analysis of the pancreas
revealed that the combination treatment resulted in an increased expression of insulin and PDX-1, and increased
insulin content.
Conclusions: The combination therapy of ViL and VaL improves both pancreatic beta-cell function and insulin
sensitivity, with a reduction of the inflammatory and cell stress milieu in mouse models of T2DM. Our results
suggest that this combination therapy exerts additive or even synergistic benefits to treat T2DM.
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Type 2 diabetes is a major global health problem associated
with high morbidity and excessive mortality. Because the
prevalence of type 2 diabetes is rapidly increasing and
current treatments are not sufficient to satisfactorily control
the disease in the majority of patients, better treatments are
still required [1]. Pancreatic beta-cell dysfunction and insu-
lin resistance are the two major pathophysiological features
of type 2 diabetes [2]. Hence, to maintain normoglycemia,
the most desirable treatment for type 2 diabetes should* Correspondence: earaki@gpo.kumamoto-u.ac.jp
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reproduction in any medium, provided the ortarget improvement of beta-cell dysfunction and insulin re-
sistance simultaneously.
Diabetic micro- and macrovascular complications
are at least partly dependent on dysglycemia itself,
which has two main components: chronic sustained
hyperglycemia and post-prandial glycemic fluctuations.
Both components lead to diabetic complications
through several major mechanisms, including activa-
tion of oxidative stress and increased chronic inflam-
matory activity [3]. Oxidative stress has been highly
and positively correlated with glycemic variability
over a daily period as assessed from the mean ampli-
tude of glycemic excursions (MAGE). In this context,
tight glycemic control, as well as suppression ofral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to achieve ideal treatment of type 2 diabetes.
Glucagon-like peptide 1 (GLP-1) is a gut-derived
incretin hormone that stimulates insulin and suppresses
glucagon, inhibits gastric emptying, and reduces ap-
petite and food intake. Because the action of incretin is
attenuated in type 2 diabetics [4], exogenous GLP-1
administration improves glycemic control [5]. Thera-
peutic approaches for enhancing incretin action include
degradation-resistant GLP-1 receptor agonists and inhibi-
tors of dipeptidyl peptidase-4 activity [6]. DPP-4 inhibitors
including vildagliptin have been reported to amplify beta-
cell mass and improve its function in a number of in vitro
and in vivo studies [7-10]. A significant and sustained in-
crease in active GLP-1 with suppression of glucagon in re-
sponse to vildagliptin has been reported in type 2 diabetes
[11]. Vildagliptin improves blood glucose stability in a
dose-independent manner [12]. Furthermore, vildagliptin
may be superior as a means to control MAGE and mean
24 h blood glucose compared with other DPP-4 inhibitors
[13]. Blunting glucose fluctuations contributes to reducing
oxidative stress and inflammation in diabetics [14]. These
results together suggest that, among DPP-4 inhibitors, vil-
dagliptin may have the best potential to achieve total gly-
cemic control and minimize glucose fluctuations.
Patients with type 2 diabetes frequently experience com-
plications such as hypertension. Inhibition of the renin-
angiotensin system (RAS), especially through the use of
angiotensin II type 1 receptor blockers (ARB) such as val-
sartan, was reported to have a preventive effect on type 2
diabetes [15,16]. In particular, a lower incidence of newly
diagnosed diabetes was confirmed in response to valsartan
treatment [17]. Recent studies have suggested that valsar-
tan increases glucose-stimulated insulin secretion (GSIS)
and insulin sensitivity in normotensive subjects with im-
paired glucose tolerance (IGT) [18]. The prospective
NAVIGATOR trial showed that treatment with valsartan
reduced type 2 diabetes incidence by 14% in subjects with
IGT [19]. ARB treatment was shown to improve GSIS and
insulin biosynthesis, and delay the onset of diabetes, in
db/db mice [20]. These observations suggest that a com-
bination of the DPP-4 inhibitor vildagliptin with the ARB
valsartan may exert beneficial effects in the treatment of
type 2 diabetes through complementary actions.Materials and methods
Animals
All animals, obtained from CLEA (CLEA Japan Inc.,
Tokyo, Japan), were housed in the Center for Animal
Resources and Development of Kumamoto University.
The experimental procedures were approved by the Ani-
mal Experimentation Ethics Committee of Kumamoto
University (B23-178, B24-128).Diet and treatment protocol
C57BL/6 mice were fed High Fat Diet 32 (HFD group)
(CLEA), and db/db mice were fed Rodent Diet CE-2
(db/db group) (CLEA). We had a total of 66 4-week-old
db/db mice and 66 6-week-old C57BL/6 J mice (2 weeks
of HFD in advance). The first 60 mice of each strain
were randomly divided into the following five groups,
and the remaining 6 mice of each strain were then ran-
domly assigned to the final 3 groups. All mice received
their respective treatments for 8 weeks:
(1) CT: placebo treatment (n = 12), (2) PHZ: Phloridzin
treatment (0.5% in diet) (n = 12), (3) ViL: Vildagliptin
treatment (1 mg/kg/day in drinking water) (n = 14), (4)
VaL: Valsartan treatment (10 mg/kg/day in drinking water)
(n = 14), (5) ViLVaL: Vildagliptin (1 mg/kg/day) and
Valsartan treatment (10 mg/kg/day) (n = 14). The levels
of ViL and VaL used in this study were chosen based on
previous studies [21,22] and represent relevant physio-
logical doses for a human clinical situation.Measurements of biochemical markers
Blood glucose was measured using a Glutest Neo (Sanwa
Chemical Co., Nagoya, Japan). The concentration of insu-
lin was measured using an insulin ELISA kit (Shibayagi,
Gunma, Japan). Serum C-reactive protein (CRP; Life Diag-
nostics Inc., West Chester, PA), tumor necrosis factor
(TNF)-α (Invitrogen, Carlsbad, CA), monocyte chemo-
attractant protein (MCP)-1 (Invitrogen), interleukin (IL)-6
(R&D Systems Inc., Minneapolis, MN), leptin (Crystal
Chem Inc., Chicago, IL) and adiponectin (Otsuka Pharma-
ceutical, Tokyo, Japan) levels were measured using the ap-
propriate ELISA kits.Intra peritoneal glucose tolerance test (GTT) and
intraperitoneal insulin tolerance test (ITT)
After 8 weeks of treatment, GTT (2.0 g/kg) and ITT
(1 U/kg for HFD or 2 U/kg for db/db) were performed fol-
lowing an intra-peritoneal injection of glucose or insulin,
as previously described [23].Pancreatic insulin content
The pancreas was rapidly removed, homogenized, and ex-
tracted in acid ethanol overnight at 4°C. The insulin con-
tent was measured using a Mouse Insulin ELISA Kit
(Shibayagi) [24].In situ measurement of nitrotyrosine
Liver tissue was dissected and immediately frozen in liquid
nitrogen. After homogenization, the content of nitrotyro-
sine was measured using NWLSS™ Nitrotyrosine ELISA
test kits (Northwest Life Science Specialties, LLC).
Figure 1 (See legend on next page.)
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Figure 1 Combination treatment with vildagliptin and valsartan decreases blood glucose in HFD and db/db mice. Weekly food intake
(A), body weight increments (B), fasting (C) and random-fed blood glucose (D) were measured during each treatment in HFD or db/db mice.
HOMA-IR and HOMA-beta were calculated using fasting blood glucose and insulin levels after 8 weeks of treatment (E and F). Values represent
mean ± SEM, n = 12 – 14. *p < 0.05, **p < 0.01 compared with the CT group. †p < 0.05 compared with the ViL group.
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The liver and muscle tissues were dissected 5 min after
injection with or without insulin (5 U/mice) via the infer-
ior vena cava and immediately frozen in liquid nitrogen.
Western blotting was performed as described previously
[24] using antibodies purchased from Cell Signaling
Technology (CST; Beverly, MA, USA), except for anti-
α-tubulin clone DM1A, which was purchased from
Millipore (Billerica, MA, USA).
Immunohistochemistry
Immunohistochemical analysis was performed as described
previously [24]. Anti-insulin antibody (diluted 1:200, Santa
Cruz (SC) Biotechnology Inc., Santa Cruz, CA), anti-
glucagon antibody (diluted 1:100, SIGMA-ALDRICH),
anti-PDX-1 antibody (diluted 1:100, CHEMICON Inter-
national Inc., Temecula, CA USA), anti-IRS2 antibody (di-
luted 1:100, SC), anti-NF-κB p65 antibody (diluted 1:100,
CST) and anti-HSP72 antibody (diluted 1:100, Stressgen
Biotechnologies, Victoria, BC, Canada) were used.
Morphometric analysis
The area of insulin positive beta-cells relative to the total
area of pancreatic tissue was calculated using Image J image
analysis software (Version 1.61; http://rsbweb.nih.gov/ij/),
using 18 sections (i.e., six sections from three different areas
of the pancreas) for each group of mice.
Statistical analysis
All data are shown as the mean ± S.E.M. Comparisons of
multiple means were performed using two-way repeated
measures analysis of variance (for homogeneous variance)
as indicated. Multiple comparisons between groups were
performed using an analysis of variance followed by Tukey’s
post-hoc test. A value of p < 0.05 was considered statisti-
cally significant.
Results
Combination treatment with vildagliptin and valsartan
decreases blood glucose
After 8 weeks of treatment, food intake (Figure 1A) and
body weight (Figure 1B) were unaltered in all groups.
Fasting blood glucose levels were significantly decreased
in PHZ (HFD: -33.3%, p = 0.027; db/db: -35.7%, p = 0.019),
ViL (HFD: -31.6%, p = 0.041; db/db: -39.8%, p = 0.032) and
ViLVaL (HFD: -35.8%, p = 0.012; db/db: -42.6%, p = 0.028)
interventions compared with the corresponding CT groups(HFD: CT: 140.3 ± 6.3 mg/dL, db/db: CT: 229.5 ± 9.6 mg/dL)
after 8 weeks of treatment (Figure 1C). There were si-
milar changes in random-fed glucose levels in the PHZ
(HFD: -27.8%, p = 0.044; db/db: -36.0%, p = 0.021), ViL
(HFD: -30.1%, p = 0.040; db/db: -33.6%, p = 0.018) and
ViLVaL (HFD: -34.9%, p = 0.029; db/db: -55.5%, p = 0.005,
Figure 1D) groups compared with CT (HFD: CT: 212.5 ±
6.8 mg/dL, db/db: CT: 523.2 ± 29.8 mg/dL).
The VaL group did not show a significant decrease in
either fasting or random-fed glucose levels (Figure 1C
and D). The most profound suppression of random glu-
cose levels was observed in ViLVaL-treated db/db ani-
mals compared with ViL-treated db/db animals (−33.0%,
p = 0.036), suggesting that the combination therapy may
have additional effects on glucose lowering.
After 8 weeks of treatment, homeostatic model assess-
ment insulin resistance (HOMA-IR) of HFD mice was sig-
nificantly decreased in PHZ (CT: 6.8 ± 1.1 PHZ: -29.0%,
p = 0.033), ViL (−21.2%, p = 0.041) and ViLVaL (−26.0%,
p = 0.015) compared with CT mice (Figure 1E). HOMA-
IR of db/db mice was significantly reduced in all treatment
groups compared with the control group (CT: 22.7 ± 2.1.
PHZ: -31.7%, p = 0.046; ViL: -21.0%, p = 0.032; VaL: -30.0%,
p = 0.028; ViLVaL: -28.2%, p = 0.024) (Figure 1E).
HOMA-beta in HFD showed a significant increase in
the PHZ (CT: 91.9 ± 19.2 PHZ: + 168.1%, p = 0.02), ViL
(+170.0%, p = 0.031) and ViLVaL (+228.3%, p = 0.018)
groups compared with CT animals (Figure 1F). HOMA-
beta in db/db was also upregulated in PHZ (CT: 86.5 ±
14.2. PHZ: +109.1%, p = 0.016), ViL (+190.9%, p = 0.003)
and ViLVaL (+202.7%, p = 0.007) groups compared with
the CT group (Figure 1F). These data indicate that PHZ,
ViL and ViLVaL treatment improved blood glucose, insu-
lin resistance and basal insulin secretion in both groups of
mice.
Combination treatment with vildagliptin and valsartan
improves both insulin resistance and insulin secretion
To further examine glucose homeostasis in these ani-
mals, we performed GTT with measurements of insulin
secretion, and ITT. After 8 weeks of treatments, GTT in
HFD mice showed that the blood glucose levels in all
treatment groups 30 min after injection were significantly
lower than those in the CT group (Figure 2A). Glucose
levels in the ViL and ViLVaL-treated groups at 60 and
90 min were also significantly lower than those in the CT
group (Figure 2A).
Figure 2 (See legend on next page.)
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Figure 2 Combination treatment with vildagliptin and valsartan improves both insulin resistance and insulin secretion in HFD and
db/db mice. Glucose tolerance was evaluated by GTT in HFD (A) or db/db (B) mice. Glucose-stimulated insulin secretion (C) and the insulinogenic
index (D) in response to the GTT are shown. Insulin sensitivity was evaluated by ITT in HFD (E) or db/db (F) mice. Values represent mean ± SEM,
n = 12 – 14. *p < 0.05, **p < 0.01 compared with the CT group. #p < 0.05 compared with the VaL group. †p < 0.05 compared with the ViL group.
Miyagawa et al. Cardiovascular Diabetology 2013, 12:160 Page 6 of 14
http://www.cardiab.com/content/12/1/160GTT in db/db mice showed that the blood glucose
levels in ViL and ViLVaL-treated groups 30, 60, 90 and
120 min after injection were significantly lower than
those in the CT group (Figure 2B). At 120 min after injec-
tion, ViL and ViLVaL treatment groups displayed a signifi-
cant decrease in blood glucose levels compared with the
VaL group (Figure 2B).
Serum insulin responses during GTT in db/db mice
were improved in PHZ, ViL and ViLVaL mice at 15 min
and in ViLVaL mice at 30 min (Figure 2C). Insulinogenic
index (I.I.) during GTT in db/db was also improved in
the PHZ, ViL and ViLVaL groups (Figure 2D). I.I. in the
ViLVaL-treated group was significantly increased even
compared with ViL monotherapy (Figure 2D).
The insulin sensitivity estimated by ITT in HFD mice
was unchanged in all treated groups (Figure 2E). In db/db
mice, only ViLVaL-treated mice showed significantly lower
glucose levels at 15 and 30 min after insulin injection
(Figure 2F).
Combination ViLVaL treatment decreases CRP, TNF-α, IL-6
and MCP-1, and increases adiponectin levels
Dysregulation of inflammatory cytokines and adipokines




CRP (ng/mL) 51.6 ± 6.1 46.1 ± 4.0 (0.18) 39
TNF-α (pg/mL) 12.9 ± 1.6 12.7 ± 1.5 (0.53) 10
IL-6 (pg/mL) 11.1 ± 1.1 10.8 ± 1.0 (0.13)
MCP-1 (pg/mL) 76.4 ± 7.3 73.5 ± 5.6 (0.21) 6
Leptin (ng/mL) 15.6 ± 1.1 15.3 ± 1.0 (0.32) 1
Adiponectin (μg/dL) 8.7 ± 0.9 8.4 ± 0.7 (0.28) 9
db/db m
CT PHZ
CRP (ng/mL) 70.1 ± 4.1 55.1 ± 2.3* (0.039) 46
TNF-α (pg/mL) 18.6 ± 1.0 15.6 ± 1.6 (0.24) 11
IL-6 (pg/mL) 17.1 ± 0.9 14.3 ± 0.8 (0.11) 13
MCP-1 (pg/mL) 118.7 ± 8.6 105.6 ± 7.3 (0.43) 73.
Leptin (ng/mL) 23.2 ± 1.4 22.6 ± 1.1 (0.18) 2
Adiponectin (μg/dL) 6.1 ± 0.6 7.2 ± 0.5 (0.07) 7.
Values represent mean ± SEM, n = 12 – 14.
*p < 0.05, **p < 0.01 compared with the CT group. †p < 0.05 compared with the ViL
The numbers in parenthesis indicate p values.and this was investigated 8 weeks after treatment in HFD
and db/db mice (Table 1).
In HFD mice, plasma CRP levels were significantly de-
creased in ViL, VaL and ViLVaL-treated mice compared
with CT mice. TNF-α levels were also significantly re-
duced in ViL, VaL and ViLVaL-treated mice compared
with CT mice. IL-6 was significantly decreased only in
ViLVaL compared with CT mice. Plasma MCP-1 levels
were significantly lower in the VaL and ViLVaL groups
compared with the CT group. Interestingly, ViLVaL showed
additional suppression of MCP-1 levels compared with ViL
monotherapy. Plasma leptin levels were unaffected by any
treatment. Plasma adiponectin levels were significantly in-
creased in ViL and ViLVaL mice compared with CT mice,
being highest in the ViLVaL group.
In db/db mice, similar trends were observed in inflam-
matory cytokines and adipokines. As a result, ViLVaL treat-
ment group showed a strong improvement in inflammatory
markers both in HFD and db/db mice.
Combination therapy attenuates insulin resistance with
alleviation of ER stress and oxidative stress in liver
To elucidate the molecular mechanism of whole-body in-
sulin sensitization in mice treated with ViL and/or VaL,D and db/db mice treated with corresponding
ice
ViL VaL ViLVaL
.7 ± 3.4* (0.027) 44.0 ± 4.9* (0.043) 35.9 ± 2.2** (0.0042)
.9 ± 0.7* (0.023) 10.0 ± 0.6* (0.029) 9.0 ± 0.6* (0.011)
9.8 ± 0.6 (0.09) 10.8 ± 0.5 (0.07) 8.7 ± 0.5* (0.032)
7.8 ± 4.5 (0.64) 59.4 ± 5.0* (0.033) 45.7 ± 3.6** † (0.003)
5.0 ± 0.9 (0.53) 15.1 ± 0.5 (0.074) 15.0 ± 0.09 (0.09)
.8 ± 0.5* (0.031) 8.8 ± 0.6 (0.09) 10.8 ± 0.5** (0.004)
ice
ViL VaL ViLVaL
.4 ± 3.9* (0.012) 53.3 ± 4.9* (0.024) 38.5 ± 3.6** (0.007)
.8 ± 0.7** (0.002) 10.1 ± 0.5** (0.0042) 10.2 ± 0.5** (0.0002)
.2 ± 0.8* (0.045) 12.1 ± 0.8* (0.043) 11.9 ± 0.8* (0.039)
5 ± 3.9** (0.0002) 68.2 ± 5.6** (0.003) 56.4 ± 3.1** (0.0005)
2.1 ± 1.1 (0.26) 23.5 ± 0.7 (0.31) 23.1 ± 0.7 (0.85)
7 ± 0.5* (0.0015) 6.9 ± 0.4 (0.078) 7.15 ± 0.5* (0.0043)
group.
Figure 3 (See legend on next page.)
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Figure 3 Combination therapy attenuates insulin resistance with alleviation of ER stress and oxidative stress in liver. Liver (A) or muscle
(B) lysates were extracted 8 weeks after initiation of each treatment in db/db mice with or without 5 units of insulin stimulation through the
inferior vena cava, and were analyzed by western blotting. PERK (C) and eIF2α phosphorylation (D) were also analyzed in liver samples without
insulin stimulation. The amount of nitrotyrosine (E) was measured in liver of db/db mice. Values represent mean ± SEM, n = 6 – 8. *p < 0.05,
**p < 0.01 significantly different from the CT group. ††p < 0.05 compared with the PHZ group.
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amined. Upon insulin stimulation in vivo, phosphorylation
of Akt in the liver was increased in response to ViL (2.03
fold), VaL (2.21 fold) and ViLVaL (2.83 fold) treatment
(Figure 3A), and was also increased in response to ViLVaL
in muscle (1.68 fold, Figure 3B).
In order to clarify the improved insulin signaling in
liver, endoplasmic reticulum (ER) stress signaling and
oxidative stress markers were assessed. Phosphorylation
of PKR-like ER kinase (PERK) was significantly de-
creased in the VaL (−40.7 ± 5.6%, p = 0.019) and ViLVaL
(−47.6 ± 6.8%, p = 0.006) treatment groups compared
with CT mice (Figure 3C). Phosphorylation of eukaryotic
translation initiation factor 2A (eIF2α) was also de-
creased in the VaL (−50.0 ± 7.6%, p = 0.005) and ViLVaL
(−49.4 ± 2.3%, p = 0.006) treatment groups (Figure 3D).
The oxidative stress marker nitrotyrosine was signifi-
cantly decreased in VaL and ViLVaL treatment groups
compared with the CT and PHZ groups (CT: 6.40 ±
1.10 nM; PHZ: +3.9%, p = 0.999; ViL: -16.7%, p = 0.818;
VaL: -52.0%, p = 0.025 (p = 0.014 vs. PHZ); ViLVaL: -54.0%,
p = 0.024 (p = 0.014, vs. PHZ: Figure 3E)). VaL and ViLVaL
treatment groups showed improved insulin signaling
accompanied by alleviation of ER stress and oxidative
stress.
Combination therapy improves hepatic lipid
accumulation
Hepatic steatosis was examined by oil red O staining in
liver of db/db mice. ViL or VaL alone showed a slight
improvement of fatty liver, and there was a marked re-
duction of lipid accumulation in response to ViLVaL
compared with the CT or PHZ groups (Figure 4A).
To further evaluate the molecular mechanisms of hep-
atic lipid reduction, the expression of heat shock protein
(HSP)72, peroxisome proliferator-activated receptor
(PPAR)α and sirtuin1 (Sirt1) were evaluated by western
blotting, because these molecules are involved in insulin
sensitivity and lipid metabolism in liver [23,25-27].
HSP72, PPARα and Sirt1 were significantly increased in the
ViLVaL group compared with all other groups (Figure 4B),
which was consistent with the decrease in lipid accumula-
tion in liver.
In order to evaluate fatty acid beta-oxidation in liver,
mRNA levels of peroxisomal acyl-CoA oxidase 1 (Acox1)and medium chain acyl-CoA dehydrogenase (Mcad)
were measured. Acox1, the first enzyme of the beta-
oxidation pathway, was 1.54 times higher compared with
control (p = 0.041, Figure 4C). Mcad, which is responsible
for initial dehydrogenation step in the beta-oxidation
cycle, was also increased 1.61 times compared with con-
trol (p = 0.03, Figure 4C).
Combination therapy contributes to maintenance of islet
morphology and increases the pancreatic insulin content
To identify the molecular mechanism of improved insulin
secretion in db/db mice treated with ViLVaL, we analyzed
the morphology of pancreatic islets using immunohisto-
chemistry. After 8 weeks of treatments, pancreatic insulin
content was significantly increased in the ViLVaL treat-
ment group compared with the CT group (CT: 82.47 ±
20.76 ng/mg; PHZ: +56.4%, p = 0.667; ViL: +77.6%, p =
0.366; VaL: +30.9%, p = 0.946; ViLVaL: +118.8%, p = 0.032:
Figure 5A).
The beta-cell area relative to whole pancreas was also
significantly increased in the ViL and ViLVaL groups
compared with the CT group (CT: 0.64 ± 0.18% vs. PHZ:
1.55 ± 0.36%, p = 0.081; ViL: 1.73 ± 0.19%, p = 0.025; VaL:
0.89 ± 0.16, p = 0.944; ViLVaL: 2.10 ± 0.34, p = 0.0018:
Figure 5B). The combination therapy group also showed
a significant increase in beta-cell area compared with
ViL monotherapy (p = 0.011, Figure 5B).
Morphological analysis showed that immuno-stained
insulin was low in CT islets, and this was increased in
the ViL and ViLVaL groups (Figure 5C–G). Nuclear
localization of pancreatic and duodenal homeobox (PDX)-
1 was only sparsely detectable in CT islets, but was in-
creased in the ViL and ViLVaL groups (CT: 1.93 ± 0.93/
islet vs. PHZ: 3.73 ± 1.34/islet, p = 0.01; ViL: 10.07 ± 2.67/
islet, p = 0.005; VaL: 4.53 ± 1.54/islet, p = 0.02; ViLVaL:
19.93 ± 4.17/islet, p = 0.0001: Figure 5H-L). Anti-apoptotic
insulin receptor substrate (IRS)-2 positive area in islets
was relatively small in CT mice and was increased in each
of the treatment groups (Figure 5M–Q). Inflammatory
signal detected by nuclear factor (NF)-κB p65 subunit nu-
clear accumulation was activated in CT islets, and was
clearly lower in ViLVaL islets (CT: 9.53 ± 2.25/islet vs.
PHZ: 7.33 ± 2.02/islet, p = 0.04; ViL: 2.60 ± 0.95/islet, p =
0.002; VaL: 2.93 ± 1.06/islet, p = 0.003; ViLVaL: 2.20 ±
0.98/islet, p = 0.0001: Figure 5R-U). The inducible HSP72
Figure 4 (See legend on next page.)
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Figure 4 ViLVaL combination therapy improves hepatic lipid accumulation. Hepatic steatosis was evaluated by Oil Red O staining of liver
tissues of db/db mice. Scale bars indicate 100 μm at × 200 magnification (A). Liver extracts were subjected to western blotting for HSP72, PPARα
and Sirt1 (B). Hepatic lipid oxidation was evaluated by measuring Acox1 and Mcad mRNA expression. Values represent mean ± SEM, n = 6 – 8.
*p < 0.05, **p < 0.01 compared with the CT group (C).
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Immuno-positive HSP72 was low in CT islets and was in-
creased in ViL, VaL and ViLVaL islets (Figure 5V–Z).
These results indicate that the combination therapy
protects beta-cells from inflammation and degradation
in db/db mice.
Discussion
The main finding of this study is that a combination
therapy of vildagliptin and valsartan significantly magni-
fied the beneficial effect of either monotherapy in diabetic
mice.
Insulin sensitizing effects
The ViLVaL combination improved insulin signaling mainly
in the liver, with attenuation of ER stress and oxidative
stress. As ViL alone shows only slight insulin sensitization,
the additional effect of VaL in ameliorating stress signals
in liver could explain this additional benefit. The RAS cas-
cade is activated in obesity, metabolic syndrome and type
2 diabetes [28]. RAS activation inhibits insulin signa-
ling through multiple mechanisms, including IRS-1 serine
phosphorylation, an increase of reactive oxygen species
(ROS) and activation of c-jun N-terminal kinase (JNK), or
TNF-α activation [28,29]. Indeed, AT1R blockade with
valsartan has been shown to suppress nicotinamide aden-
ine dinucleotide phosphate (NA(D)PH) oxidase p22phox
and gp91phox [30], ER stress [31] and NF-κB activation
[32], resulting in reduced oxidative stress and inflamma-
tion. In this study, valsartan ameliorated the inflammatory
milieu in liver, resulting in enhancement of insulin action.
HSP72 is a major inducible HSP against several stresses
such as heat, ischemia or hypoxia, which protects cells
through JNK inhibition [25]. The HSP72 level is decreased
in type 2 diabetes and restoration of HSP72 improves in-
sulin resistance and glucose homeostasis in mice [23-26].
We observed significant HSP72 up-regulation in liver in
response to the ViLVaL combination, suggesting this also
contributes to insulin sensitization.
Vildagliptin alone modulates the expression of genes
important for lipid metabolism [7]. GLP-1 signaling
stimulates PPARα and Sirt1 in liver, which in turn en-
hances fatty acid oxidation and attenuates inflammatory
signals. The improvement of hepatic steatosis and pre-
sumably inflammation is likely due to activation of GLP-
1R on hepatocytes, because others have shown that exe-
natide stimulates hepatocyte expression of PPARα andPPARγ that improve hepatic fatty acid oxidation, lipid
export, and insulin sensitivity [33]. We observed a sig-
nificant increase of HSP72, PPARα and Sirt1 with ameli-
oration of hepatic steatosis, particularly in the combined
treatment group, suggesting that not only vildagliptin,
but also valsartan may participate in activating this path-
way. Moreover, hepatic fatty acid beta-oxidation, evalu-
ated by assessment of Acox1 and Mcad RNA levels, was
enhanced by the combination treatment, although the
lipogenic pathway was not altered (data not shown).
Beta-cell protecting effects
Cellular stresses such as ER stress and/or oxidative stress
are key components in the pathophysiology of type 2
diabetes. In fact, pancreatic beta-cell specific C/EBPbeta
transgenic mice exhibit diabetes and decreased beta-cell
mass associated with increased apoptosis, decreased pro-
liferation, and aggravated ER stress, and these can be
restored by oral administration of vildagliptin [34].
Treatment of rats with vildagliptin significantly increased
insulin content and decreased inflammatory markers
such as nitric oxide and TNF-α [35,36]. Chronic admin-
istration of vildagliptin in IRS-2 KO mice improved glu-
cose metabolism and suppressed beta-cell apoptosis,
suggesting that vildagliptin may also activate beta-cell
proliferation independent of IRS-2 axis [37]. HFD-
induced glucose intolerance and beta cell inflammation
were both prevented by chronic treatment with vilda-
gliptin [10]. We observed a beta-cell protective effect of
ViLVaL in the islets of db/db mice. ViL alone increased
the proportion of beta-cells but there was not a signifi-
cant increase in insulin content. The ViLVaL combin-
ation significantly increased both insulin content and the
proportion of beta-cells, as well as up-regulating PDX-1
and HSP72, and attenuating NF-κB. We also found that
IRS-2 was up-regulated in the treated islets. This effect
may also contribute to the protection of beta-cells from
apoptosis. HSP72 can attenuate NF-κB nuclear transloca-
tion by inhibiting the inhibitor of κB (IκB)αphosphoryla-
tion [25]. This indicates that the combination therapy
attenuates pancreatic local inflammation, thus leading
to beta-cell protection.
Attenuation of chronic inflammation
We observed a significant reduction of circulating in-
flammatory markers such as CRP, TNF-α, IL-6 and
MCP-1, and an increase of adiponectin, in both HFD
Figure 5 (See legend on next page.)
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Figure 5 ViLVaL combination therapy contributes to maintenance of islet morphology and increases the insulin content of the
pancreas. Insulin content was measured in pancreatic extracts (A). The proportion of beta-cells to the whole pancreas was calculated using
insulin-stained pancreatic sections (B). Sections of pancreas were immunostained for insulin with glucagon (C to G), PDX-1 (H to L), IRS-2 (with
DAPI; M to Q), NF-κB p65 subunits (R to U) or HSP72 (V to Z). Scale bars indicate 20 μm at × 400 magnification. Values represent mean ± SEM,
n = 6 – 8. *p < 0.05, **p < 0.01 compared with the CT group. †p < 0.05 compared with the ViL group.
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and profoundly improved these markers, indicating that
the systemic chronic inflammatory milieu is alleviated.
These cytokines are mainly produced by adipose tissues
and macrophages. The RAS blockade decreases adipo-
cyte size and adipose tissue inflammatory markers, and
improves glucose homeostasis in rodents [20,38,39].
Valsartan treatment also reduces abdominal adipocyte
size and macrophage infiltration in IGT subjects. These
findings suggest that interventions with ViLVaL may
attenuate adipose tissue inflammation, thereby con-
tributing to the improvement of whole body glucose
homeostasis [40].
Serum DPP-4 levels correlate with adipocyte size and
adipocytes potentially represent an important source of
DPP-4 in obesity, which impairs insulin signaling [41].
Inhibiting DPP-4 by vildagliptin may directly influence
the insulin resistant effect of circulating DPP-4 itself.
We have demonstrated anti-inflammatory benefits of
ViL in diabetic mice, however some researchers have re-
ported that ViL may not have cardio-protective effects
in a rat model of myocardial infarction [42]. An under-
lying diabetic phenotype might be necessary to observe
any cardio-protective effects of ViL through its anti-
inflammatory potency. This possibility needs to be eluci-
dated in further studies.
The benefits of valsartan in combination with vildagliptin
The combination therapy of vildagliptin and valsartan in
db/db mice leads to improvement of islet ROS produc-
tion, apoptotic events, beta-cell mass, and whole body
glucose homeostasis [22]. The expression of NAD(P)H
oxidase subunits is also significantly decreased by a simi-
lar combination resulting in decreased ROS production
with GLP-1 up-regulation [30]. The decrease of vascular
oxidative stress and inflammatory reactions in response
to the combination therapy is also more prominent than
monotherapy with valsartan or vildagliptin analogues
[30]. These data support our findings, and we have fur-
ther described the attenuation of systemic and local in-
flammation, hepatic steatosis, ER stress and HSP72
induction. We also found beneficial effects on glucose
metabolism in the PHZ group, but the beneftts on insu-
lin sensitization, cell stress attenuation and inflammation
were relatively small, suggesting that the combination of
a DPP-4 inhibitor with an ARB may have advantageouseffects in addition to just lowering glucose, which is the
case with PHZ.
Although this combined therapy reduced inflamma-
tory cytokines and increased adiponectin, attenuated ER
stress, and increased insulin content and proportion of
beta-cells, the effect of this combination on glucose me-
tabolism was relatively modest in GTT. Because a DPP-
4 inhibitor works in the food-ingested state, an intraperi-
toneal glucose challenge may have represented a lesser
stimulation than food ingestion, and thus led to rela-
tively smaller effects. It is also possible that a longer
treatment period with ViLVaL may have led to more
pronounced glucose improvement effects, because the
differences in glucose levels between treatment groups
appeared to increase with time.
In conclusion, the combination of vildagliptin and val-
sartan shows additive or even synergistic effects in insulin
action, hepatic lipid oxidation and beta-cell protection
mediated by attenuation of cellular stresses and systemic/
local inflammation. This combination may be useful to
ameliorate insulin resistance and beta-cell failure simul-
taneously, and could further delay vascular complications
in type 2 diabetes patients.
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